Literature DB >> 12531127

Therapeutic use of sleep deprivation in depression.

Henner Giedke1, Frank Schwärzler.   

Abstract

Total sleep deprivation (TSD) for one whole night improves depressive symptoms in 40-60% of treatments. The degree of clinical change spans a continuum from complete remission to worsening (in 2-7%). Other side effects are sleepiness and (hypo-) mania. Sleep deprivation (SD) response shows up in the SD night or on the following day. Ten to 15% of patients respond after recovery sleep only. After recovery sleep 50-80% of day 1 responders suffer a complete or partial relapse; but improvement can last for weeks. Sleep seems to lead to relapse although this is not necessarily the case. Treatment effects may be stabilised by antidepressant drugs, lithium, shifting of sleep time or light therapy. The best predictor of a therapeutic effect is a large variability of mood. Current opinion is that partial sleep deprivation (PSD) in the second half of the night is equally effective as TSD. There are, however, indications that TSD is superior. Early PSD (i.e. sleeping between 3:00 and 6:00) has the same effect as late PSD given equal sleep duration. New data cast doubt on the time-honoured conviction that REM sleep deprivation is more effective than non-REM SD. Both may work by reducing total sleep time. SD is an unspecific therapy. The main indication is the depressive syndrome. Some studies show positive effects in Parkinson's disease. It is still unknown how sleep deprivation works.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12531127

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  60 in total

1.  Sleep Disturbances in Pediatric Depression.

Authors:  Uma Rao
Journal:  Asian J Psychiatr       Date:  2011-12

Review 2.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Increased sleep pressure reduces resting state functional connectivity.

Authors:  Philipp G Sämann; Carolin Tully; Victor I Spoormaker; Thomas C Wetter; Florian Holsboer; Renate Wehrle; Michael Czisch
Journal:  MAGMA       Date:  2010-05-15       Impact factor: 2.310

Review 4.  Sleep and perinatal mood disorders: a critical review.

Authors:  Lori E Ross; Brian J Murray; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2005-07       Impact factor: 6.186

Review 5.  Life-long hippocampal neurogenesis: environmental, pharmacological and neurochemical modulations.

Authors:  Eleni Paizanis; Sabah Kelaï; Thibault Renoir; Michel Hamon; Laurence Lanfumey
Journal:  Neurochem Res       Date:  2007-04-04       Impact factor: 3.996

Review 6.  Circadian genes, rhythms and the biology of mood disorders.

Authors:  Colleen A McClung
Journal:  Pharmacol Ther       Date:  2007-02-28       Impact factor: 12.310

Review 7.  Psychiatric disorders and sleep.

Authors:  Andrew D Krystal
Journal:  Neurol Clin       Date:  2012-11       Impact factor: 3.806

8.  Effects of Restricted Time in Bed on Antidepressant Treatment Response: A Randomized Controlled Trial.

Authors:  J Todd Arnedt; Leslie M Swanson; Richard R Dopp; Holli S Bertram; Ann J Mooney; Edward D Huntley; Robert F Hoffmann; Roseanne Armitage
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

Review 9.  An attentional scope model of rumination.

Authors:  Anson J Whitmer; Ian H Gotlib
Journal:  Psychol Bull       Date:  2012-12-17       Impact factor: 17.737

10.  Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?

Authors:  Mariana Bendlin Calzavara; Wladimir Agostini Medrano; Raquel Levin; Sonia Regina Kameda; Monica Levy Andersen; Sergio Tufik; Regina Helena Silva; Roberto Frussa-Filho; Vanessa Costhek Abílio
Journal:  Schizophr Bull       Date:  2008-02-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.